TY  - JOUR
A1  - Sriha, Jessica
A1  - Louis-Brennetot, Caroline
A1  - Pierre-Eugène, Cécile
A1  - Baulande, Sylvain
A1  - Raynal, Virginie
A1  - Kramdi, Amira
A1  - Adameyko, Igor
A1  - Ernsberger, Uwe
A1  - Deller, Thomas
A1  - Delattre, Olivier
A1  - Janoueix-Lerosey, Isabelle
A1  - Rohrer, Hermann
T1  - BET and CDK inhibition reveal differences in the proliferation control of sympathetic ganglion neuroblasts and adrenal chromaffin cells
T2  - Cancers
N2  - Neuroblastoma arising from the adrenal differ from ganglionic neuroblastoma both genetically and clinically, with adrenal tumors being associated with a more severe prognosis. The different tumor properties may be linked to specific tumor founder cells in adrenal and sympathetic ganglia. To address this question, we first set up cultures of mouse sympathetic neuroblasts and adrenal chromaffin cells. These cultures were then treated with various proliferation inhibitors to identify lineage-specific responses. We show that neuroblast and chromaffin cell proliferation was affected by WNT, ALK, IGF1, and PRC2/EZH2 signaling inhibitors to a similar extent. However, differential effects were observed in response to bromodomain and extraterminal (BET) protein inhibitors (JQ1, GSK1324726A) and to the CDK-7 inhibitor THZ1, with BET inhibitors preferentially affecting chromaffin cells, and THZ1 preferentially affecting neuroblasts. The differential dependence of chromaffin cells and neuroblasts on BET and CDK signaling may indicate different mechanisms during tumor initiation in sympathetic ganglia and adrenal.
KW  - chromaffin cell
KW  - sympathetic
KW  - neuroblast
KW  - bromodomain and extraterminal (BET) protein
KW  - transcriptional cyclin-dependent kinase
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/73499
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-734999
SN  - 2072-6694
N1  - Funding:
Wilhelm Sander Stiftung (H.R.; grant 2018-042.1); Mayent-Rothschild Foundation and INCa (H.R.). High-throughput sequencing was performed using the ICGex NGS platform of the Institut Curie supported by the grants ANR-10-EQPX-03 (Equipex) and ANR-10-INBS-09-08 (France Génomique Consortium) from the Agence Nationale de la Recherche ("Investissements d’Avenir" program), by the ITMO-Cancer Aviesan (Plan Cancer III), and by the SiRIC-Curie program (SiRIC Grant INCa-DGOS-465 and INCa-DGOSInserm_12554). The Delattre and Adameyko teams are supported by the ERC Synergy program "Kill-or-differentiate".
N1  - Raw data for RNA-seq are available in the Gene Expression Omnibus (GEO) under the accession number GSE200379 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE200379).
VL  - 14
IS  - 11, art.  2755
SP  - 1
EP  - 21
PB  - MDPI
CY  - Basel
ER  -